Bionexus Gene Lab Stock Probability of Future Stock Price Finishing Over 0.39
| BGLC Stock | USD 0.25 0.04 13.79% |
BioNexus |
BioNexus Gene Target Price Odds to finish over 0.39
The tendency of BioNexus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 0.39 or more in 90 days |
| 0.25 | 90 days | 0.39 | about 50.0 |
Based on a normal probability distribution, the odds of BioNexus Gene to move over $ 0.39 or more in 90 days from now is about 50.0 (This BioNexus Gene Lab probability density function shows the probability of BioNexus Stock to fall within a particular range of prices over 90 days) . Probability of BioNexus Gene Lab price to stay between its current price of $ 0.25 and $ 0.39 at the end of the 90-day period is about 49.9 .
Given the investment horizon of 90 days BioNexus Gene has a beta of 0.34 suggesting as returns on the market go up, BioNexus Gene average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BioNexus Gene Lab will be expected to be much smaller as well. Additionally BioNexus Gene Lab has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. BioNexus Gene Price Density |
| Price |
Predictive Modules for BioNexus Gene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioNexus Gene Lab. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioNexus Gene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioNexus Gene is not an exception. The market had few large corrections towards the BioNexus Gene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioNexus Gene Lab, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioNexus Gene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 0.04 | |
Ir | Information ratio | -0.18 |
BioNexus Gene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioNexus Gene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioNexus Gene Lab can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioNexus Gene Lab generated a negative expected return over the last 90 days | |
| BioNexus Gene Lab has some characteristics of a very speculative penny stock | |
| BioNexus Gene Lab has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.77 M. Net Loss for the year was (2.63 M) with profit before overhead, payroll, taxes, and interest of 2.19 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (1.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| BioNexus Gene Lab has a poor financial position based on the latest SEC disclosures | |
| Roughly 44.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNexus Gene Lab faces Nasdaq delisting over price rule By Investing.com - Investing.com Nigeria |
BioNexus Gene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioNexus Stock often depends not only on the future outlook of the current and potential BioNexus Gene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioNexus Gene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.9 M | |
| Cash And Short Term Investments | 5.9 M |
BioNexus Gene Technical Analysis
BioNexus Gene's future price can be derived by breaking down and analyzing its technical indicators over time. BioNexus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of BioNexus Gene Lab. In general, you should focus on analyzing BioNexus Stock price patterns and their correlations with different microeconomic environments and drivers.
BioNexus Gene Predictive Forecast Models
BioNexus Gene's time-series forecasting models is one of many BioNexus Gene's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BioNexus Gene's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about BioNexus Gene Lab
Checking the ongoing alerts about BioNexus Gene for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for BioNexus Gene Lab help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| BioNexus Gene Lab generated a negative expected return over the last 90 days | |
| BioNexus Gene Lab has some characteristics of a very speculative penny stock | |
| BioNexus Gene Lab has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.77 M. Net Loss for the year was (2.63 M) with profit before overhead, payroll, taxes, and interest of 2.19 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (1.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| BioNexus Gene Lab has a poor financial position based on the latest SEC disclosures | |
| Roughly 44.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNexus Gene Lab faces Nasdaq delisting over price rule By Investing.com - Investing.com Nigeria |
Check out BioNexus Gene Backtesting, BioNexus Gene Valuation, BioNexus Gene Correlation, BioNexus Gene Hype Analysis, BioNexus Gene Volatility, BioNexus Gene History as well as BioNexus Gene Performance. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.